Abbott Hits Sandoz With New Niaspan Patent Suit

Law360, New York (February 18, 2011, 1:43 PM EST) -- Abbott Laboratories has launched another patent infringement suit against Sandoz Inc. in an effort to keep a generic version of blockbuster cholesterol drug Niaspan off the market.

Mary B. Graham of Morris Nichols Arsht & Tunnell LLP lodged the suit on behalf of Abbott and its subsidiary Abbott Respiratory LLC in the U.S. District Court for the District of Delaware on Wednesday, accusing Sandoz of infringing Abbott's U.S. Patent Numbers 6,080,428 and 6,469,035.

The suit follows Sandoz's filing of an amended abbreviated new drug application with...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.